Navigation Links
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Date:6/16/2008

management," said Mr. Kranda. "I look forward to working with the talented employees of Anesiva to achieve these goals and build long-term value for stockholders."

"The members of the Anesiva board welcome Michael and thank John for his dedicated leadership over the last 8 years," said Mr. Ferguson. "We appreciate John's vision and dedication in leading Anesiva."

"I am proud of the significant accomplishments that the Anesiva team has made over the last several years," said Mr. McLaughlin. "With Michael in place to lead the company forward, I will work closely with him as a consultant to ensure a smooth transition."

About Anesiva's Diverse Pipeline of Pain Products

Anesiva, Inc. is a commercial-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first product, Zingo(TM), is scheduled for launch later this month in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The company filed an sNDA with the FDA to expand the label to include adults in March 2008.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-look
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... 20, 2014 The 6th Annual ... held on October 29-30 in San Francisco, CA. This ... and government researchers and clinicians focused on addressing and ... , In the twelve years since the sequencing of ... been introduced with pharmacogenetic information in the label and ...
(Date:8/20/2014)... ear could improve the health of your heart, researchers ... Leeds used a standard TENS machine like those designed ... the tragus, the small raised flap at the front ... canal. , The stimulation changed the influence of the ... signals that can drive failing hearts too hard. , ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Systems, Inc. (OTC Bulletin Board: OMCM) announced that it ... for the purpose of resolving the patent infringement lawsuit ... into a licensing arrangement with DataSci. OmniComm CEO ... come to an agreement in this matter. This ...
... ATLANTA, April 15 CryoLife, Inc. (NYSE: CRY ... processing company, announced today that 2009 first quarter financial results ... that day, the Company will hold a teleconference call and ... results, followed by a question and answer session hosted by ...
... DCGN ) today announced that in order to ... under consideration, it has,elected to utilize a 30-day grace ... outstanding 3.5% Senior Convertible Notes due 2011. , ... deCODE is a biopharmaceutical company developing drugs and ...
Cached Biology Technology:OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC 2CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results 2deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes 2
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2
... (OTC Bulletin Board: CICI) Communication Intelligence Corporation ... supplier of electronic signature solutions for business process ... leader** in biometric signature verification announced today its ... year ended December 31, 2008.Total revenues for the ...
... ILInsects such as honeybees and bumble bees are predictable in ... one flower to an adjacent cluster of flowers in the ... direct affect on their ability to hunt for pollen and ... pollen moves from one plant to another. The study of ...
... National Institute of Child Health and Development (NICHD) of the ... Medicine of Yeshiva University a $7.5 million grant to establish ... (SCCPIR).One of only 13 such centers in the country and ... will focus on a wide range of diseases of the ...
Cached Biology News:Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 6Flight of the bumble (and honey) bee 2NIH funds research center for women's reproductive health at Einstein 2NIH funds research center for women's reproductive health at Einstein 3
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Biology Products: